ImmunityBio Q2 FY26 net loss widens to $230.4 million; revenue rises 92% YoY to $50.7 million
IBRX•Quarterly results and operating expenses
- ImmunityBio posted Q2 net product revenue of $50.7 million, up 92% year-over-year and up 15% sequentially.
- Net loss attributable to common stockholders widened to $230.4 million; adjusted net loss (non-GAAP) narrowed to $81.0 million.
- R&D expense rose to $60.8 million; SG&A expense increased to $51.8 million.
- First-half net product revenue climbed to $94.8 million, up 121% versus the prior-year period.
- Cash, cash equivalents and marketable securities totaled $357.4 million; the FDA set a Jan. 6, 2027 PDUFA date for an ANKTIVA sBLA.
Related News
MaxLinear, Core Micro Systems collaborate on Panther-based hardware-accelerated OpenZFS storage solutions
MXL•
Veru wins US patent allowance for enobosarm-semaglutide weight-loss regimen claims
VERU•
